Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
International Journal of Medicinal Mushrooms
IF: 1.423 5-Year IF: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Print: 1521-9437
ISSN Online: 1940-4344

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v13.i5.10
pages 401-426

Medicinal Mushrooms for Glycemic Control in Diabetes Mellitus: History, Current Status, Future Perspectives, and Unsolved Problems (Review)

Hui-Chen Lo
Department of Nutritional Science, Fu Jen Catholic University, New Taipei City, Taiwan
Solomon P. Wasser
N.G. Kholodny Institute of Botany, NAS of Ukraine, 2 Tereshchenkovskaya Str., Kiev 01004, Ukraine; International Center for Cryptogamic Plants and Fungi, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel


Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia with defects in insulin secretion and/or insulin resistance. Despite great efforts that have been made in the understanding and management of diabetes, its prevalence continues to grow. Recent discoveries have opened up an exciting opportunity for developing new types of therapeutics from medicinal mushrooms to control DM and its complications. To date, more and more active components including polysaccharides and their protein complexes, dietary fibers, and other compounds extracted from fruiting bodies, cultured mycelium, or cultured broth of medicinal mushrooms have been reported as to having anti-hyperglycemic activity. These compounds exhibit their antidiabetic activity via different mechanisms. This article presents an overview of the multiple aspects of diabetes mellitus and the efficacy and mechanism of medicinal mushrooms for glucose control in diabetes, including the inhibition of glucose absorption, protection of beta-cell damage, increase of insulin release, enhancement of antioxidant defense, attenuation of inflammation, modulation of carbohydrate metabolism pathway, and regulation of insulin-dependent and insulin-independent signaling pathways. However, there is insufficient evidence to draw definitive conclusions about the efficacy of individual medicinal mushrooms for diabetes. In addition, the wide variability, the lack of standards for production, and the lack of testing protocols to assess product quality are still problems in producing medicinal mushroom products. Moreover, well-designed randomized controlled trials with long-term consumption are needed to guarantee the bioactivity and safety of medicinal mushroom products for diabetic patients.

Articles with similar content:

Medicinal Mushrooms in Human Clinical Studies. Part I. Anticancer, Oncoimmunological, and Immunomodulatory Activities: A Review
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 4
Solomon P. Wasser
An Overview of Culinary and Medicinal Mushrooms in Neurodegeneration and Neurotrauma Research
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 3
Chai-Chee Ng, Kah-Hui Wong, Gowri Kanagasabapathy, Yoon-Yen Yow, Vikineswary Sabaratnam
Mechanisms Behind the Anti-inflammatory Actions of Insulin
Critical Reviews™ in Immunology, Vol.31, 2011, issue 4
Morley D. Hollenberg, Eric Hyun, Rithwik Ramachandran, Nathalie Vergnolle
Taking Ingredients as an Entry Point to Explore the Relationship between the Shaggy Ink Cap Medicinal Mushroom, Coprinus comatus (Agaricomycetes), and Diabetes Mellitus (Review)
International Journal of Medicinal Mushrooms, Vol.21, 2019, issue 5
Fangxue Xu, Shiyuan Wang, Mengmeng Zheng, Chunchao Han, Hong Guo, Yujuan Li, Xiaowei Cui, Xiaozhi Xi, Hui Cao
The Efficacy and Toxicity of Using the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), and Its Products in Chemotherapy (Review)
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 10
Martina Cizmarikova